Futura Medical PLC has announced the appointment of Roy Davis as a Non-Executive Director. Davis brings extensive commercial experience in medical devices companies and a successful track record of scaling companies and delivering substantial value for shareholders. He has held leadership positions at several publicly quoted med tech companies, including Optos plc and Gyrus Group plc. Currently, he serves as Non-Executive Chair at LungLife AI plc, Foster and Freeman, and Rair Health Ltd. Davis expressed his excitement about joining Futura, emphasizing the company's innovative solutions in the sexual health sector and the exciting opportunities ahead.

Jeff Needham, Chairman of Futura Medical, highlighted Davis's significant commercial expertise and proven track record of creating substantial shareholder value. He expressed confidence that Davis's appointment will enhance the depth and breadth of experience on the Futura Board as the company continues to monetize its key asset, Eroxon, move towards profitability, and deliver on its strategy.

Roy Davis, the newly appointed Non-Executive Director, expressed his delight in joining the Futura Board and conveyed his eagerness to work with the Board and Executive Team to help execute the strategy and deliver shareholder value. In accordance with Schedule 2(g) of the AIM Rules for Companies, Davis disclosed his current and previous directorships/partnerships in the last five years.

Futura Medical plc, listed on AIM, is a pharmaceutical company developing a portfolio of innovative sexual health products based on its proprietary, transdermal DermaSys® technology. The company's topical gel formulation, MED3000, is a novel treatment for erectile dysfunction (ED) sold in Europe and the UK under the brand name Eroxon®. Futura has conducted two Phase 3 studies using MED3000 in ED, enabling the company to be granted a CE Mark in 2021 and US marketing authorization. Both studies demonstrated that MED3000 presents an effective clinically proven treatment for ED with a rapid speed of onset and a favorable benefit versus risk profile, ideally suited for an 'Over the Counter' classification.